Scarica l'app Stockscreener
1.81
3.21%
-0.06
Dopo l'orario di chiusura:
1.82
0.01
+0.55%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GANX Giù?
Forum
Previsione
Precedente Chiudi:
$1.87
Aprire:
$1.86
Volume 24 ore:
714.60K
Relative Volume:
1.23
Capitalizzazione di mercato:
$65.07M
Reddito:
$210.70K
Utile/perdita netta:
$-21.37M
Rapporto P/E:
-1.6455
EPS:
-1.1
Flusso di cassa netto:
$-21.10M
1 W Prestazione:
-12.98%
1M Prestazione:
+11.04%
6M Prestazione:
+4.02%
1 anno Prestazione:
-38.01%
Intervallo 1D:
$1.77
$1.90
Intervallo di 1 settimana:
$1.77
$2.13
Portata 52W:
$1.41
$3.19
Gain Therapeutics Inc Stock (GANX) Company Profile
Nome
Gain Therapeutics Inc
Settore
Industria
Telefono
(301) 500-1556
Indirizzo
4800 HAMPDEN LANE, BETHESDA
Confronta GANX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.81 | 73.34M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-08-14 | Ripresa | Oppenheimer | Outperform |
| 2021-04-12 | Iniziato | BTIG Research | Buy |
| 2021-04-12 | Iniziato | Oppenheimer | Outperform |
Gain Therapeutics Inc Borsa (GANX) Ultime notizie
Is Gain Therapeutics Inc. still worth holding after the dipWeekly Profit Report & Verified Stock Trade Ideas - newser.com
Gain Therapeutics to Attend the 2025 Maxim Growth Summit - MarketScreener
Oct 22: Gene Mack to Speak — Gain Therapeutics at 2025 Maxim Growth Summit on Neurodegenerative Panel - Stock Titan
How to forecast Gain Therapeutics Inc. trends using time seriesWeekly Investment Summary & Free Long-Term Investment Growth Plans - newser.com
What recovery options are there for Gain Therapeutics Inc.Quarterly Growth Report & Weekly High Return Opportunities - newser.com
BTIG Reiterates Gain Therapeutics (GANX) Buy Recommendation - Nasdaq
Intraday pattern recognizer results for Gain Therapeutics Inc.Buy Signal & Community Verified Trade Alerts - newser.com
How to build a dashboard for Gain Therapeutics Inc. stockMarket Growth Report & Entry Point Confirmation Alerts - newser.com
Institutional scanner results for Gain Therapeutics Inc.July 2025 Chart Watch & Reliable Momentum Entry Alerts - newser.com
Gain Therapeutics, Inc Hosts Key Opinion Leader Event on GT-02287 - TradingView
Gain Therapeutics (NASDAQ:GANX) Given “Buy” Rating at HC Wainwright - Defense World
How risky is Gain Therapeutics Inc. stock nowJuly 2025 Patterns & Entry and Exit Point Strategies - newser.com
Certain Options of Gain Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-OCT-2025. - MarketScreener
Certain Common Stock of Gain Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-OCT-2025. - MarketScreener
Will Gain Therapeutics Inc. stock benefit from sector rotationEarnings Trend Report & Weekly High Return Forecasts - newser.com
Is Gain Therapeutics Inc. stock entering bullish territory2025 Historical Comparison & Smart Investment Allocation Tips - newser.com
HC Wainwright & Co. Reiterates Gain Therapeutics (GANX) Buy Recommendation - Nasdaq
What does recent volatility data suggest for Gain Therapeutics Inc.Earnings Miss & High Return Trade Opportunity Guides - newser.com
Published on: 2025-10-10 04:06:35 - newser.com
Eric Richman Resigns from Gain Therapeutics Board - TipRanks
Allosteric small molecule therapies in PD, with Gene Mack - pharmaphorum
Is Gain Therapeutics Inc. stock cheap at current valuationBreakout Watch & Daily Stock Trend Watchlist - newser.com
Is it time to cut losses on Gain Therapeutics Inc.2025 Momentum Check & Free Expert Verified Stock Movement Alerts - newser.com
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease - The Manila Times
Gain Therapeutics to Host Virtual KOL Event on GT-02287 and Parkinson's Disease Research - Quiver Quantitative
Applying big data sentiment scoring on Gain Therapeutics Inc.Weekly Gains Report & AI Driven Price Forecasts - newser.com
Gain Therapeutics (NASDAQ:GANX) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Gain Therapeutics Supports Reliable Data Management In Labs - Kalkine Media
Gain Therapeutics (NASDAQ:GANX) Given New $7.00 Price Target at Maxim Group - Defense World
Is Gain Therapeutics Inc a good long term investmentVolume Spike Alerts & Small Budget Big Profits - earlytimes.in
Maxim Group Maintains Gain Therapeutics (GANX) Buy Recommendation - Nasdaq
Maxim Group Raises Price Target for Gain Therapeutics (GANX) to - GuruFocus
Gain Therapeutics reports preliminary Phase 1b data for Parkinson’s drug GT-02287 - Investing.com
Stock Traders Buy High Volume of Gain Therapeutics Call Options (NASDAQ:GANX) - MarketBeat
Gain Therapeutics reports positive early data from Parkinson’s trial - Investing.com
Gain Therapeutics reports positive early data from Parkinson’s trial By Investing.com - Investing.com Australia
Gain Therapeutics Reports Positive Interim Data from Phase 1b Study of GT-02287 in Parkinson’s Disease - Quiver Quantitative
Gain Therapeutics' GT-02287 Shows UPDRS Improvement in 9 by Day 90 | GANX Stock News - Stock Titan
What to do if you’re stuck in Gain Therapeutics Inc.Breakout Watch & Daily Stock Trend Watchlist - newser.com
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 61.6% in September - MarketBeat
Detecting price anomalies in Gain Therapeutics Inc. with AITrade Analysis Report & Verified Stock Trade Ideas - newser.com
Does Gain Therapeutics Inc. stock trade at a discount to peers2025 Breakouts & Breakdowns & Community Shared Stock Ideas - newser.com
Gain Therapeutics (NASDAQ:GANX) versus Karyopharm Therapeutics (NASDAQ:KPTI) Head-To-Head Review - Defense World
What moving averages say about Gain Therapeutics Inc.July 2025 Retail & Capital Efficiency Focused Ideas - newser.com
Applying Wyckoff theory to Gain Therapeutics Inc. stockWall Street Watch & Free Community Supported Trade Ideas - newser.com
Gain Therapeutics Inc Azioni (GANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):